Product Description
Mechanisms of Action: HO1 Inducer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | China | Korea
Approved Indications: None
Known Adverse Events: None
Company: ZERIA
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Polaprezinc](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Taste Disorders
Phase 2: Mucositis|Digestive System Cancer|Colorectal Cancer|Liver Cancer|Leukemia|Lymphoma|Intestinal Diseases|Gastrointestinal Cancer|Mouth Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2300070469 | N/A |
Not yet recruiting |
Helicobacter Infections |
2024-02-29 |
|
PEACe | P2 |
Completed |
Prostate Cancer |
2023-01-20 |
|
ChiCTR1900028329 | N/A |
Recruiting |
Unknown |
2022-12-31 |
|
ToPaZ Study | P2 |
Completed |
Liver Cancer|Digestive System Cancer|Lymphoma|Colorectal Cancer|Intestinal Diseases|Mouth Cancer|Leukemia|Mucositis|Gastrointestinal Cancer |
2022-07-01 |